Bajaj Healthcare logs 11% revenue growth in Q1, PBT up 13%
Standalone revenue from continuing operations rose to ₹165.63 crore in the June 2026 quarter; board also approved continuation of independent director beyond age 75.
— 1 earlier story on Bajaj Healthcare Ltd. →What's new
- Revenue from continuing ops rose 11% YoY to ₹165.63 cr
- PBT from continuing ops increased to ₹16.46 cr from ₹14.53 cr
- Board approved continuation of independent director Gopalakrishnan Kesavan post-75
Why this matters
The growth is modest and in line with recent trends, unlikely to shift the narrative for a stock trading at a P/E of 47.8. The director approval is standard governance. This is a routine quarterly update with no surprise.
What we're watching
- Sustainability of revenue growth in coming quarters
- Any improvement in ROE and debt reduction
- Potential for new product approvals or contract wins
The full read
Bajaj Healthcare reported a modest uptick in Q1 FY27. Standalone revenue from continuing operations came in at ₹165.63 crore, up 11% year-on-year, while PBT improved to ₹16.46 crore from ₹14.53 crore. The board also approved the continuation of independent director Gopalakrishnan Kesavan beyond age 75 — a routine governance item. For a stock trading at 47.8 times trailing earnings, this quarter's steady but unspectacular growth does little to justify the premium. With trailing revenue and PAT both deeply negative, the company has ground to make up before the narrative shifts. Expect a neutral market reaction.
Questions answered
- What were Bajaj Healthcare's Q1 FY27 revenue and growth rate?
- Standalone revenue from continuing operations was ₹165.63 crore, up 11% year-on-year.
- How did profit before tax perform in Q1?
- PBT from continuing operations grew to ₹16.46 crore from ₹14.53 crore in the same quarter last year.
- Did the board approve any corporate action besides results?
- Yes, the board approved the continuation of non-executive independent director Gopalakrishnan Kesavan after he turns 75 in January 2027, subject to shareholder consent.
- What is Bajaj Healthcare's current market valuation?
- The company has a market cap of about ₹1,018 crore, with a trailing P/E of 47.8 and an ROE of 8.5%.
- How does this quarter compare to the company's trailing performance?
- Trailing revenue declined -0.9% and PAT fell -304.5%, so this quarter's growth marks a positive reversal, albeit modest.
Bajaj Healthcare Ltd.
Latest quarter · Jun 2026
Strength & growth
Story so far
All notes on BAJAJHCARE →- 20 Jul 2026 · 7:45 PM IST Bajaj Healthcare logs 11% revenue growth in Q1, PBT up 13%
- 1d ago Bajaj Healthcare Q1 revenue up 11%; results reiterate known numbers